{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-25-000055","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.428900+00:00","generated_at":"2026-05-20T03:00:05.216387+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inhaled KB707 monotherapy achieves 27% ORR in advanced NSCLC; updated to 36%","bullets":["27% ORR (3/11 PR) in heavily pre-treated NSCLC; extended follow-up yields 36% (4/11 PR).","Median DOR and PFS not reached; responses durable.","Safety well-tolerated: most TRAEs Grade 1/2, no Grade 4/5; MTD not reached.","Combination cohort with pembrolizumab enrolling for NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-25-000055","json":"https://secwatch.observer/filing/0001711279-25-000055.json","markdown":"https://secwatch.observer/filing/0001711279-25-000055.md","text":"https://secwatch.observer/filing/0001711279-25-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000055/0001711279-25-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000055/krys-20250602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:00:05.216387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}